Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1701 plus bevacizumab and platinum-doublet chemotherapy for EGFR-mutant advanced or metastatic nonsquamous non-small cell lung cancer
CTR20212944Phase 3Active
- Sponsor
- Suzhou Shengdiya Biopharmaceuticals
- Start
- Feb 2022
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of retlirafusp alfa in non-small cell lung cancer (NSCLC), sponsored by Suzhou Shengdiya Biopharmaceuticals. Started Feb 2022; status: active.
02
Drugs
retlirafusp alfa
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20212944.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212944.